Short-term anti-HIV activity of the combination of didanosine and hydroxyurea

Antiviral Therapy

Volumn 1, Issue 3, 1996, Pages 189-193

  Clotet, Bonaventura ^a   Ruiz, Lidia ^a   Cabrera, Cecilia ^a   Ibáñez, Angela ^a   Cañadas, Maria Paz ^b   Sirera, Guillem ^a   Romeu, Joan ^a   Vila, Jorge ^c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b General Lab   (Spain)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; HYDROXYUREA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; DRUG COMBINATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MALE; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV-1; HUMANS; HYDROXYUREA; MALE; RNA, VIRAL;

EID: 0030201567     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F & Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New England Journal of Medicine 1995; 332:1132-1136.
2. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, MacMahon RP, Bonds DR & The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine 1995; 332:1317-1322.
3. Malley S, Grange J, Hamedi-Sangsari F & Vila J. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds. Lancet 1994; 343:1292.
4. Malley S, Grange J, Hamedi-Sangsari F & Vila J. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proceedings of the National Academy of Sciences USA 1994; 91:11017-11021.
5. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J & Gallo R. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication. Science 1994; 266:801-805.
6. Giacca M, Zanussi S, Comar M, Simonelli, Vaccher E, De Paoli P & Tirelli U. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. Journal of Infections Diseases 1996; 174:204-209.
7. Gao WY, Cara A, Gallo RC & Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences USA 1993; 90:8925-8928.
8. Ruiz L, Clotet B, Cabrera C, Canadas MP, Sirera G, Romeu J & Raventos A. Viral load changes at one month interval with didanosine and hydroxyurea combination. 4th International Workshop on HIV Drug Resistance, Sardinia, Italy, 6-9 July 1995. Abstr. 46.
9. Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F, Grange J, Malley S, Hamedi-Sangsari F & Vila J. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1 infected individuals. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995; 10:36-40.
10. Donehower R. An overview of the clinical experience with hydroxyurea. Seminars in Oncology 1992; 19(Suppl. 9):11-19.
11. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L & Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. Journal of Clinical Microbiology 1994, 32:292-303.
12. Hollinger FB, Bremer JW, Myers LE, Gold JWM, McQuay L & The NIH/NIAID/DAIDS/ACTG/Virology Laboratories. Standardization and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. Journal of Clinical Microbiology 1992; 30:1787-1794.
13. Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reicheldelfer PS & Kuritzkes DR. Standardized microtiter assay for determination of syncytium inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. Journal of Clinical Microbiology 1994; 32:2291-2294.
14. Aboulker JP, Autran B, Beldjord K, Touraine F & Debré P. Consistency of routine measurements of CD4, CDS peripheral blood lymphocytes. Journal of Immunological Methods 1992; 154:155-161.
15. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C & Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. New England Journal of Medicine 1996; 334:1011-1017.
16. Eron JJ, Benoit SL, Jemsek J, Macarthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallen MA & Rubin M. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New England Journal of Medicine 1995; 333:1662-1669.